Pathophysiological role of mast cells in collagen-induced arthritis: Study with a cysteinyl leukotriene receptor antagonist, montelukast

European Journal of Pharmacology

Volumn 548, Issue 1-3, 2006, Pages 158-166

  Shiota, Naotaka ^a   Shimoura, Keiko ^a   Okunishi, Hideki ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Arthritis; Cysteinyl leukotriene; Mast cell; TNF

Indexed keywords

MESSENGER RNA; MONTELUKAST; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; X RAY ANALYSIS;

ACETATES; ANIMALS; ARTHRITIS, EXPERIMENTAL; LEUKOTRIENE ANTAGONISTS; MALE; MAST CELLS; MICE; MICE, INBRED DBA; QUINOLINES; RNA, MESSENGER; STEM CELL FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748695985     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.07.046     Document Type: Article

References (48)

1. Bromley M., Fisher W.D., and Woolley D.E. Mast cells at sites of cartilage erosion in the rheumatoid joint. Ann. Rheum. Dis. 43 (1984) 76-79
2. Buchan G., Barrett K., Turner M., Chantry D., Maini R.N., and Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 73 (1988) 449-455
3. Carsons S.E., Santiago-Schwarz F., and Diola C. Detection and quantitation of stem cell factor (kit ligand) in the synovial fluid of patients with rheumatic disease. J. Rheumatol. 27 (2000) 2798-2800
4. Ceponis A., Konttinen Y.T., Takagi M., Xu J.W., Sorsa T., Matucci-Cerinic M., Santavirta S., Bankl H.C., and Valent P. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J. Rheumatol. 25 (1998) 2304-2314
5. Chibana K., Ishii Y., Asakura T., and Fukuda T. Up-regulation of cysteinyl leukotriene 1 receptor by IL-13 enables human lung fibroblasts to respond to leukotriene C4 and produce eotaxin. J. Immunol. 170 (2003) 4290-4295
6. Chu C.Q., Field M., Feldmann M., and Maini R.N. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34 (1991) 1125-1132
7. Crisp A.J., Chapman C.M., Kirkham S.E., Schiller A.L., and Krane S.M. Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum. 27 (1984) 845-851
8. Durie F.H., Fava R.A., and Noelle R.J. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin. Immunol. Immunopathol. 73 (1994) 11-18
9. Eum S.Y., Maghni K., Hamid Q., Campbell H., Eidelman D.H., and Martin J.G. Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. Am. J. Respir. Cell Mol. Biol. 28 (2003) 25-32
10. Fauler J., Thon A., Tsikas D., Von Der Hardt H., and Frolich J.C. Enhanced synthesis of cysteinyl leukotrienes in juvenile rheumatoid arthritis. Arthritis Rheum. 37 (1994) 93-97
11. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev., Immunol. 2 (2002) 364-371
12. Feldmann M., Brennan F.M., and Maini R.N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14 (1996) 397-440
13. Figueroa D.J., Borish L., Baramki D., Philip G., Austin C.P., and Evans J.F. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis. Clin. Exp. Allergy 33 (2003) 1380-1388
14. Fireman E., Schwartz Y., Mann A., and Greif J. Effect of montelukast, a cysteinyl receptor antagonist, on myofibroblasts in interstitial lung disease. J. Clin. Immunol. 24 (2004) 418-425
15. Firestein G.S., Alvaro-Gracia J.M., and Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 144 (1990) 3347-3353
16. Godfrey H.P., Ilardi C., Engber W., and Graziano F.M. Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum. 27 (1984) 852-856
17. Gordon J.R., and Galli S.J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346 (1990) 274-276
18. Griffiths R.J., Pettipher E.R., Koch K., Farrell C.A., Breslow R., Conklyn M.J., Smith M.A., Hackman B.C., Wimberly D.J., Milici A.J., et al. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 517-521
19. Ichiyama T., Hasegawa S., Umeda M., Terai K., Matsubara T., and Furukawa S. Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin. Exp. Allergy 33 (2003) 802-807
20. Kakizoe E., Li S.H., Kobayashi Y., Nishikori Y., Dekio S., and Okunishi H. Increases in mast cells and chymase in fibroproliferative paws of collagen-induced arthritic mice. Inflamm. Res. 48 (1999) 318-324
21. Kanaoka Y., and Boyce J.A. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. 173 (2004) 1503-1510
22. Kiener H.P., Hofbauer R., Tohidast-Akrad M., Walchshofer S., Redlich K., Bitzan P., Kapiotis S., Steiner G., Smolen J.S., and Valent P. Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum. 43 (2000) 164-174
23. Kobayashi Y., and Okunishi H. Mast cells as a target of rheumatoid arthritis treatment. Jpn. J. Pharmacol. 90 (2002) 7-11
24. Koshihara Y., Isono T., Oda H., Karube S., and Hayashi Y. Measurement of sulfidopeptide leukotrienes and their metabolism in human synovial fluid of patients with rheumatoid arthritis. Prostaglandins Leukot. Essent. Fat. Acids 32 (1988) 113-119
25. Lee D.M., Friend D.S., Gurish M.F., Benoist C., Mathis D., and Brenner M.B. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297 (2002) 1689-1692
26. Li S.H., Kobayashi Y., Yamauchi Y., Gonda T., and Tsunematsu T. Suppressive effects of a herbal formula, TBL-1, on type II collagen-induced arthritis in DBA/1J mice. Clin. Exp. Pharmacol. Physiol. 23 (1996) 236-240
27. Maeba S., Ichiyama T., Ueno Y., Makata H., Matsubara T., and Furukawa S. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann. Allergy, Asthma, & Immun. 94 (2005) 670-674
28. Malone D.G., Wilder R.L., Saavedra-Delgado A.M., and Metcalfe D.D. Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. Arthritis Rheum. 30 (1987) 130-137
29. Mellor E.A., Maekawa A., Austen K.F., and Boyce J.A. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 7964-7969
30. Mellor E.A., Austen K.F., and Boyce J.A. Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through an interleukin 4-regulated pathway that is inhibited by leukotriene receptor antagonists. J. Exp. Med. 195 (2002) 583-592
31. Olsen N.J., and Stein C.M. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2167-2179
32. Olsson N., Ulfgren A.K., and Nilsson G. Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann. Rheum. Dis. 60 (2001) 187-193
33. Piguet P.F., Grau G.E., Vesin C., Loetscher H., Gentz R., and Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77 (1992) 510-514
34. Ramires R., Caiaffa M.F., Tursi A., Haeggstrom J.Z., and Macchia L. Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem. Biophys. Res. Commun. 324 (2004) 815-821
35. Saxne T., Palladino Jr. M.A., Heinegard D., Talal N., and Wollheim F.A. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31 (1988) 1041-1045
36. Shiota N., Fukamizu A., Takai S., Okunishi H., Murakami K., and Miyazaki M. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J. Hypertens. 15 (1997) 431-440
37. Shiota N., Okunishi H., Takai S., Mikoshiba I., Sakonjo H., Shibata N., and Miyazaki M. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 99 (1999) 1084-1090
38. Shiota N., Rysa J., Kovanen P.T., Ruskoaho H., Kokkonen J.O., and Lindstedt K.A. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J. Hypertens. 21 (2003) 1935-1944
39. Shiota N., Kakizoe E., Shimoura K., Tanaka T., and Okunishi H. Effect of mast cell chymase inhibitor on the development of scleroderma in tight-skin mice. Br. J. Pharmacol. 145 (2005) 424-431
40. Sjostrom M., Jakobsson P.J., Juremalm M., Ahmed A., Nilsson G., Macchia L., and Haeggstrom J.Z. Human mast cells express two leukotriene C4 synthase isoenzymes and the CysLT1 receptor. Biochim. Biophys. Acta 1583 (2002) 53-62
41. Sousa A.R., Parikh A., Scadding G., Corrigan C.J., and Lee T.H. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N. Engl. J. Med. 347 (2002) 1524-1526
42. Tetlow L.C., and Woolley D.E. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann. Rheum. Dis. 54 (1995) 896-903
43. Tomari S., Matsuse H., Machida I., Kondo Y., Kawano T., Obase Y., Fukushima C., Shimoda T., and Kohno S. Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics. Clin. Exp. Allergy 33 (2003) 795-801
44. Trentham D.E., Townes A.S., and Kang A.H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 146 (1977) 857-868
45. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9784-9788
46. Woolley D.E., and Tetlow L.C. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res. 2 (2000) 65-74
47. Wooley P.H., Dutcher J., Widmer M.B., and Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151 (1993) 6602-6607
48. Yocum D.E., Esparza L., Dubry S., Benjamin J.B., Volz R., and Scuderi P. Characteristics of tumor necrosis factor production in rheumatoid arthritis. Cell. Immunol. 122 (1989) 131-145